RxDoctor Payments Data

Kristin Templin, MD

Internal Medicine · Meadville, PANPI 1992737332

Payments from drug & device makers

$9,042in general payments, 2019–2025

Across 533 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$739
  • Lilly USA, LLC$723
  • AbbVie$589
  • Merck$502
  • Astellas Pharma US Inc$493
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$9,019100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,042 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$125,389
Medicare patients
788
Services billed
2,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$128,795
OzempicSemaglutide68$69,035
JardianceEmpagliflozin82$67,894
MounjaroTirzepatide36$45,614
Repatha SureclickEvolocumab62$40,531
XareltoRivaroxaban31$29,757
TrulicityDulaglutide17$22,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$22,680
FarxigaDapagliflozin Propanediol14$15,800
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$13,550
Praluent PenAlirocumab26$12,400
MyrbetriqMirabegron15$11,520
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$10,840
SynthroidLevothyroxine Sodium94$4,754
Pantoprazole Sodium286$4,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$423$128,795125 claims
Novo NordiskOzempic$1,010$69,03568 claims
Lilly USA, LLCMounjaro, Trulicity$723$68,35753 claims
Boehringer IngelheimJardiance$353$67,89482 claims
GSKTrelegy Ellipta, Anoro Ellipta$392$36,22954 claims
Johnson & JohnsonXarelto$398$29,75731 claims
AstraZenecaFarxiga$401$15,80014 claims
Astellas Pharma US IncMyrbetriq$493$11,52015 claims
AbbVieSynthroid$589$4,75494 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$33$3,341397 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Meadville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →